Sugi Predict

Sugi Predict / Compounds / SCHEMBL178786

SCHEMBL178786

SCHEMBL178786

O=C(NC1(C(=O)O)CCCCC1)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.50
▸ EPHX2 P34913 1/20 0.50
▸ DPP8 Q6V1X1 1/20 0.44
▸ DPP9 Q86TI2 1/20 0.44
▸ FABP7 O15540 2/20 0.43
▸ FABP5 Q01469 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ CTSL P07711 4/20 0.43
▸ CTSS P25774 4/20 0.43
▸ CTSB P07858 2/20 0.43
▸ CASP3 P42574 2/20 0.43
▸ CTSK P43235 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30594467 1.00 KMT2A (0.50) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL7401413 1.00 KMT2A (0.50) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL29624561 1.00 KMT2A (0.50) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL29624551 1.00 KMT2A (0.50) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL30594472 0.99 KMT2A (0.51) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL29624557 0.99 KMT2A (0.51) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL178775 0.99 KMT2A (0.51) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL178778 0.96 KMT2A (0.51) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL29624572 0.96 KMT2A (0.51) KMT2AEPHX2DPP8DPP9FABP7
SCHEMBL30752687 0.96 KMT2A (0.51) KMT2AEPHX2DPP8DPP9FABP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5385910-A Gem-distributed esters of rapamycin AMERICAN HOME PRODUCTS CORPORATION (US) 1995-01-31 — — US claimed
US-12637520-B2 Conjugation chemistry for catalytic antibody 38C2 UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2026-05-26 — — US disclosed
US-20260001928-A1 CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY CORTERIA PHARMACEUTICALS (FR) 2026-01-01 — — US disclosed
EP-4482578-B1 CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY CORTERIA PHARMACEUTICALS (FR) 2025-12-24 — — EP disclosed
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 — — US disclosed
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20250230193-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-07-17 — — US disclosed
CN-119930738-A The method comprises the following steps of68Ga-marked molecular probe targeting VLA-4, preparation method and application thereof 江苏省原子医学研究所 2025-05-06 — — CN disclosed
EP-4512818-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS Chugai Seiyaku Kabushiki Kaisha (JP) 2025-02-26 — — EP disclosed
US-20250051394-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-02-13 — — US disclosed
US-20010016207-A1 Dipeptide nitrile cathepsin K inhibitors NOVARTIS AG (CH) 2001-08-23 — — US disclosed
WO-2001058886-A1 DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS NOVARTIS AG (CH) 2001-08-16 — — WO disclosed
WO-2001058471-A2 NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE INTERMUNE, INC. (US) 2001-08-16 — — WO disclosed
CN-1278244-A Dipeptide nitriles NOVARTIS AG (CH) 2000-12-27 — — CN disclosed
EP-1028942-A2 DIPEPTIDE NITRILES Novartis AG (CH) 2000-08-23 — — EP disclosed
WO-1999024460-A2 DIPEPTIDE NITRILES NOVARTIS AG (CH) 1999-05-20 — — WO disclosed
EP-0846127-A1 ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY Novartis AG (CH) 1998-06-10 — — EP disclosed
WO-1997008193-A1 ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY NOVARTIS AG (CH) 1997-03-06 — — WO disclosed
WO-1997007131-A1 ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES NOVARTIS AG (CH) 1997-02-27 — — WO disclosed
US-5385910-A Gem-distributed esters of rapamycin AMERICAN HOME PRODUCTS CORPORATION (US) 1995-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637520-B2 Conjugation chemistry for catalytic antibody 38C2 IGLV6-57, SETD1A, KDM4C KMT2A 5/4885EPHX2 3835/4885DPP8 485/4885
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS KRAS, HRAS, NRAS KMT2A 1250/4885EPHX2 3153/4885DPP8 2543/4885
US-20250051394-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS KRAS, HRAS, NRAS KMT2A 1250/4885EPHX2 3153/4885DPP8 2543/4885
US-20010016207-A1 Dipeptide nitrile cathepsin K inhibitors CTSK, CTSC, CTSS KMT2A 3931/4885EPHX2 1756/4885DPP8 43/4885
US-20250230193-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS KRAS, HRAS, NRAS KMT2A 1250/4885EPHX2 3153/4885DPP8 2543/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS KMT2A 3145/4885EPHX2 3594/4885DPP8 2120/4885
US-20260001928-A1 CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY GIPR, NPY2R, NPY1R KMT2A 2458/4885EPHX2 4247/4885DPP8 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.